Facilitation of left ventricular function recovery post percutaneous coronary intervention by levosimendan

International Journal of Cardiology

Volumn 168, Issue 1, 2013, Pages 237-242

  Qarawani, Dahud ^a   Cohen, Ayala ^b   Nahir, Menachem ^a   Hasin, Yonathan ^a  

^a Cardiovascular Institute Bruch Padea Medical Center   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Heart failure; Hibernation; Levosimendan; PCI

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; HEPARIN; LEVOSIMENDAN; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INTERVENTION STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS;

HEART FAILURE; HIBERNATION; LEVOSIMENDAN; PCI;

AGED; AGED, 80 AND OVER; CARDIOTONIC AGENTS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PYRIDAZINES; RECOVERY OF FUNCTION; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84883783873     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.09.088     Document Type: Article

References (23)

1. P. Chareonthaitawee, B.J. Gersh, P.A. Araoz, and R.J. Gibbons Revascularization in severe left ventricular dysfunction: the role of viability testing J Am Coll Cardiol 46 2005 567 574
2. E. Alderman, L.D. Fisher, and P. Litwin Results of coronary artery surgery in patients with poor left ventricular dysfunction (CASS) Circulation 68 1983 785 795
3. E.P. Bounous, D.B. Mark, and B.G. Pollock Surgical survival benefits for coronary disease patients with left ventricular dysfunction Circulation 78 1988 I151 I157
4. E. Velazquez, K. Lee, and M. Deja N Engl J Med 364 2011 1607 1616
5. S.P. Sedlis, K.B. Ramanathan, D.A. Morrison, G. Sethi, J. Sacks, and W. Henderson Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcome with bypass (the AWESOME randomized trial and registry) Am J Cardiol 94 2004 118 120
6. J.H. O'Keefe, J.J. Allan, and B.D. McCallister Angioplasty versus bypass surgery for multivessel coronary artery disease with left ventricular ejection fraction < or = 40% Am J Cardiol 71 1993 897 901
7. K. Toda, K. MacKenzie, and M.R. Mehra Revascularization in severe ventricular dysfunction (15% < or = LVEF < or = 30%): a comparison of bypass grafting and percutaneous intervention Ann Thorac Surg 74 2002 2082 2087
8. B. Szkróbka, A. Gruszka, and R. Parma Comparison of effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in patients with ischemic cardiomyopathy Am J Cardiol 99 1 Jan 1 2007 36 41
9. E. Carluccio, P. Biagioli, and G. Alunni Effect of revascularizing viable myocardium on left ventricular diastolic function in patients with ischaemic cardiomyopathy EHJ 30 2009 1501 1509
10. S. Sonntag, S. Sundberg, L.A. Lehtonen, and F.X. Kleper The calcium sensitizer levosimendan improves the function of stunned myocardiumafter percutaneous transluminal coronary angioplasty in acute myocardial ischemia J Am Coll Cardiol 43 12 2004 2177 2182
11. J.T. Parissis, F. Panou, D. Farmakis, S. Adamopoulos, G. Fillippatos, and I. Paraskevaidis Effects of levosimendan on markets of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure Am J Cardiol 96 3 2005 423 426
12. D. Pagano, F. Fath-Ordoubadi, K.J. Beatt, J.N. Townend, R.S. Bonser, and P.G. Camici Effects of coronary revascularisation on myocardial blood flow and coronary vasodilator reserve in hibernating myocardium Heart 85 2001 208 212
13. O. Yildiz Vasodilating mechanisms of levosimendan: involvement of K + channels J Pharmacol Sci 104 2007 1 5
14. I.N. Jamali, J.R. Kersten, and P.S. Pagel Intracoronary levosimendan enhances contractile function of stunned myocardium Anesth Analg 85 1997 23 29
15. K. Tarakji, R. Brunken, and P. McCarthy Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction Circulation 113 2006 230 237
16. J. Bax, A. Schinkel, and E. Boersma Early versus delayed revascularization in patients with ischemic cardiomyopathy and substantial viability: impact on outcome Circulation 108 2003 II-39
17. K.C. Allman, L.J. Shaw, R. Hachamovitch, and J.E. Udelson Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis J Am Coll Cardiol 39 2002 1151 1158
18. D. Mark, W. Pan, and E. Clapp-Channing N Engl J Med 360 2009 774 783
19. H. Samady, J. Elefteriades, B. Abbott, J. Mattera, C. McPherson, and F. Wackers Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome Circulation 100 1999 1298 1304
20. D.P. Figgitt, P.S. Gillies, and K.L. Goa Levosimendan Drugs 61 2001 613 627
21. J.R. Kersten, M.W. Montgomery, P.S. Pagel, and D.C. Warltier Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels Anesth Analg 90 1 2000 5 11
22. F. Follath, J.G. Cleland, and H. Just Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial Lancet 360 2002 196 202
23. Mebazaa AL, Nieminen M, Packer M, Cohen-Solal A, Kivikko M. Levosimendan vs dobutamine for patients with acute decompensated heart failure. The Survive Trial. JAMA; 297:1883-1891.